Analysts Set Cabaletta Bio, Inc. (NASDAQ:CABA) PT at $15.33

Cabaletta Bio, Inc. (NASDAQ:CABA) has been given a consensus rating of “Moderate Buy” by the seven research firms that are presently covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, one has assigned a hold rating and five have assigned a buy rating to the company. The average 1 year price target among brokers that have updated their coverage on the stock in the last year is $15.3333.

A number of equities analysts have recently weighed in on CABA shares. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $30.00 price target on shares of Cabaletta Bio in a research note on Monday, May 4th. Jefferies Financial Group reiterated a “buy” rating on shares of Cabaletta Bio in a research note on Wednesday, June 3rd. Weiss Ratings reissued a “sell (d-)” rating on shares of Cabaletta Bio in a report on Friday, July 17th. Wells Fargo & Company decreased their price objective on shares of Cabaletta Bio from $4.00 to $3.00 and set an “equal weight” rating on the stock in a report on Friday, August 14th. Finally, Wall Street Zen lowered shares of Cabaletta Bio from a “hold” rating to a “sell” rating in a research report on Saturday, June 13th.

Institutional Investors Weigh In On Cabaletta Bio

A number of institutional investors and hedge funds have recently modified their holdings of CABA. BlackRock Inc. acquired a new position in Cabaletta Bio during the second quarter worth $33,447,000. Adage Capital Partners GP L.L.C. grew its holdings in Cabaletta Bio by 142.9% in the second quarter. Adage Capital Partners GP L.L.C. now owns 8,829,758 shares of the company’s stock valued at $13,421,000 after purchasing an additional 5,195,285 shares during the last quarter. Millennium Management LLC grew its holdings in Cabaletta Bio by 298.5% in the fourth quarter. Millennium Management LLC now owns 2,736,912 shares of the company’s stock valued at $5,994,000 after purchasing an additional 2,050,099 shares during the last quarter. T. Rowe Price Investment Management Inc. increased its position in shares of Cabaletta Bio by 17.9% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 9,858,257 shares of the company’s stock valued at $21,590,000 after buying an additional 1,495,768 shares in the last quarter. Finally, Stonepine Capital Management LLC purchased a new position in shares of Cabaletta Bio in the second quarter valued at $2,852,181,000.

Cabaletta Bio News Summary

Here are the key news stories impacting Cabaletta Bio this week:

• Positive Sentiment: HC Wainwright raised its EPS forecasts for Cabaletta Bio’s third and fourth quarters of 2026, full-year 2026, all quarters of 2027, full-year 2027, and full-year 2028. The revisions generally reflect narrower expected losses, including improved forecasts of $(1.35) for FY2026 versus $(1.51) previously, $(1.29) for FY2027 versus $(1.48), and $(0.74) for FY2028 versus $(1.41). The changes suggest analysts see a faster path toward reduced cash losses. HC Wainwright earnings estimate revisions
• Neutral Sentiment: Despite the improved estimates, Cabaletta Bio is still expected to report substantial losses in the near term, with consensus calling for $(1.34) EPS for the current fiscal year. HC Wainwright’s forecasts also imply that profitability is not expected until 2030, when it projects positive EPS of $0.89. Cabaletta Bio earnings estimates
• Negative Sentiment: HC Wainwright lowered its longer-term EPS forecasts for FY2029 to $(0.68) from $(0.64) and FY2030 to $0.89 from $1.11. The cuts indicate some moderation in expectations for the company’s eventual earnings power. Separately, Wells Fargo reduced its price target for CABA to $3.00, limiting near-term valuation upside and adding pressure to the stock’s outlook. Wells Fargo cuts Cabaletta Bio price target

Cabaletta Bio Price Performance

CABA opened at $2.91 on Friday. Cabaletta Bio has a 12 month low of $1.40 and a 12 month high of $4.23. The stock has a market capitalization of $493.36 million, a P/E ratio of -1.85 and a beta of 3.30. The business has a 50 day simple moving average of $2.87 and a 200-day simple moving average of $3.06.

Cabaletta Bio (NASDAQ:CABA) last announced its quarterly earnings data on Thursday, August 13th. The company reported ($0.34) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.37) by $0.03. Research analysts anticipate that Cabaletta Bio will post -1.34 EPS for the current year.

About Cabaletta Bio

Cabaletta Bio is a clinical-stage biotechnology company pioneering chimeric autoantibody receptor T cell (CAAR-T) therapies for B cell–mediated autoimmune diseases. Its proprietary platform engineers patient-derived T cells to selectively target and eliminate pathogenic B cells that produce disease-driving autoantibodies, with the aim of preserving overall immune function and reducing off-target toxicity.

The company’s lead candidate, DSG3-CAART, is being evaluated in pemphigus vulgaris, a rare blistering disorder caused by autoantibodies against desmoglein 3.